In detail, Hechtman et al. reported a high level of concordance between pan-Trk testing and RNA-based NGS across 22 NTRK fusion-positive and 20 fusion-negative tumors of various histotypes, with one false-negative colorectal cancer sample carrying the ETV6/NTRK3 fusion (specificity—100%; sensitivity—95.2%) [22]. This evidence concerns the gene NTRK3 and colorectal cancer.